Sipagladenant

DB17080InvestigationalSmall molecule

KW-6356 is a selective antagonist of adenosine A2A receptors developed by Kyowa Kirin.

Mechanism: Pharmacologically active on Adenosine receptor A2a
Curator reviewed
Code names: KW-6356

Resolves to

Compound

Targets

What you can answer from here — as of May 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Sipagladenant, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.